Many psychiatrists and neurosurgeons felt that St. The competitive outlook seemed even more promising when Medtronic abandoned its trial of DBS of VC/VS for depression after a failed futility analysis. The company got approval to expand the trial to 20 sites in 2011. The company’s BROADEN trial for DBS of Brodmann area 25 for treatment of depression was well underway and initial data looked promising. Jude had signed a deal with two of the foremost researchers in the field, Andres Lozano of the University of Toronto and Helen Mayberg of Emory University. All three devices received CE Mark approval for dystonia in Europe earlier this year.īut the company’s fortunes in DBS were particularly thought to lie in the market for treatment-resistant depression. The company’s Libra and LibraXP devices are approved for treatment of Parkinson’s disease in Europe and Australia and its compact rechargeable Brio system garnered a favorable reaction from clinicians when it was introduced. In 2012, the company announced that a clinical trial for treatment of migraine using occipital nerve stimulation failed to meet its primary endpoint.ĭespite the setbacks, many industry observers pinned their hopes on St. Jude has been impacted by many of the other issues facing large medical device companies, including regulatory hurdles, failed clinical trials, and government inquiries. Indeed, the neuromodulation division itself imploded and is now part of an implantable electronic systems division under the leadership of Eric Fain, who previously headed the cardiac rhythm management division.Īside from the staff cutbacks and defections, St. Jude neuromodulation executives have left the firm to join other neuromodulation companies. Rohan Hoare, a Chavez protege who had been tapped as his replacement to run the neuromodulation division, is also out, and was recently hired by Cyberonics. Chris Chavez has left the company to head up a promising firm in the cardiac device market. and several newer competitors in the neuromodulation space. Jude’s neuromodulation franchise has lost some of its edge, and the company is now in a battle to keep up with Boston Scientific Corp. Jude picked up market share in the sizeable spinal cord stimulation market and began making noises in the market for DBS, which Medtronic dominated. Jude had seen before in the cardiac device market. In the years that followed the acquisition, the team put together by ANS CEO Chris Chavez stayed in place in Plano, TX and immediately put competitive pressure on Medtronic, a competitor St. Paul, MN manufacturer of neuromodulation systems, became the number two player in the industry behind Medtronic when it acquired Advanced Neuromodulation Systems in 2005. Jude Medical Struggles to Regain Traction in Neuromodulation Market Jude Medical Neuromodulation Division said, "Neurostimulation offers chronic pain patients a therapy that can deliver sustainable relief.St. Jude Medical, Eon device can provide sustainable therapy and maintain a reasonable recharge interval for 10 years, resulting in fewer battery replacement surgeries.Ĭhris Chavez, president of the St. In addition, the company said Eon Mini has the longest-lasting battery life of any rechargeable spinal cord stimulation device. The Eon Mini neurostimulator has a thin 10 mm profile and weighs 29 grams or around 1 oz. The company said Eon Mini's thin profile and greater implant depth makes it less noticeable and more comfortable for patients. Spinal cord stimulators manage chronic pain of the trunk or limbs and pain from failed back surgery by delivering low levels of electrical pulses to the spinal cord, which interrupt or mask the pain signals' transmission to the brain. According to the company, Eon Mini is the world's smallest, longest-lasting rechargeable neurostimulator and the first rechargeable spinal cord stimulator to be approved for use in Japan. ( STJ) Thursday said its rechargeable spinal cord stimulator to treat chronic pain, Eon Mini, received approval from the Japanese Ministry of Health, Labor and Welfare.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |